Novartis AG (NOVN) Receives Average Rating of “Hold” from Analysts
Shares of Novartis AG (VTX:NOVN) have been given a consensus rating of “Hold” by the sixteen brokerages that are currently covering the firm, MarketBeat.com reports. Three equities research analysts have rated the stock with a sell recommendation, six have assigned a hold recommendation and seven have given a buy recommendation to the company. The average 1 year target price among brokerages that have covered the stock in the last year is CHF 86.41.
Several equities research analysts have weighed in on NOVN shares. Morgan Stanley set a CHF 88 price objective on Novartis and gave the stock a “buy” rating in a research note on Friday, October 20th. UBS set a CHF 78 target price on Novartis and gave the company a “neutral” rating in a research report on Monday, October 23rd. Kepler Capital Markets set a CHF 87 target price on Novartis and gave the company a “buy” rating in a research report on Monday, August 28th. set a CHF 90 target price on Novartis and gave the company a “buy” rating in a research report on Thursday, September 7th. Finally, Goldman Sachs Group set a CHF 80 target price on Novartis and gave the company a “neutral” rating in a research report on Tuesday, October 17th.
Shares of Novartis (NOVN) opened at CHF 83.85 on Friday. Novartis has a 1-year low of CHF 69.50 and a 1-year high of CHF 85.40.
ILLEGAL ACTIVITY WARNING: This piece of content was first posted by Daily Political and is the property of of Daily Political. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of international copyright laws. The original version of this piece of content can be accessed at https://www.dailypolitical.com/2017/12/15/novartis-ag-novn-receives-average-rating-of-hold-from-analysts.html.
Novartis Company Profile
Novan, Inc, a clinical-stage drug development company, focuses on the development and commercialization of nitric oxide-based therapies in dermatology. Its lead product candidate is SB204, a cosmetically elegant topical gel that targets multiple mechanisms of action for the treatment of acne vulgaris.
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.